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Abstract
Background: It is well documented that there is some correlation between poor oral health in the form of
periodontal disease and coronary heart disease (CHD). It is unclear whether this correlation is due to a causal
relationship or shared underlying disorder such as inflammation. A suitable integrated model of the CHD
pathogenetic pathways relevant to periodontal disease may help to elucidate the association. Such a model is
currently not available in literature.
Methods: A previously developed integrated model of CHD was used to investigate potential pathogenetic
pathways linking periodontal disease to CHD biomarkers.
Results: The integrated model was created to provide insight into possible higher-order biological interactions
underlying CHD and periodontal disease. In order to simplify these interactions a novel ‘connection graph’ was
developed. It quantitatively illustrates the relationship between periodontal disease and various serological
biomarkers of CHD. The pathogenesis of periodontitis shows various possible pathways which could link
periodontitis to CHD pathogenesis.
Conclusion: An integrated model of CHD was developed which provides a summary of the potential CHD effects
of periodontal disease. Further research must refine and validate the model.
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Background
The largest cause of death globally is Coronary heart dis-
ease (CHD) [1]. It is also well documented that poor oral
health in the form of periodontal disease is associated with
an increased risk for CHD [2–6]. Whether this prevalence
is directly linked to a causal effect of periodontitis or the
effect of a shared underlying disorder such as inflamma-
tion has not been determined [7]. It is however clear that
although there is a correlation between periodontal dis-
ease and CHD, the extent of this correlation and the use-
fulness thereof are not yet evident [2–7].
It may thus prove beneficial to quantify and elucidate
the underlying pathogenetic effect of periodontal disease
on the pathogenesis of CHD. Using a previously de-
scribed integrated model of CHD [8] we therefore inves-
tigated the possible interconnectivity of periodontal
disease and the pathogenesis and pathophysiological
traits attributed to CHD.
The existing model graphically describes all the hypo-
thetical pathogenetic pathways of CHD [8]. Some of
these pathways can then be measured by serum bio-
markers to give an indication of the degree of risk such
a pathway represents. The model was used in this study
to holistically review the interconnections between oral
health pathogenesis and the pathogenesis of CHD. The
theory is that where these conditions overlap there is the
possibility for causal interaction which should be investi-
gated in detail.
The vision behind the model is that it could be vali-
dated over time by calibrating it on a patient specific
basis. Patients can be compared with themselves over
time. Once the sample size of patient specific calibrated
models is large enough the model could give new insight
on the underlying workings of CHD. However, in the ab-
sence of existing studies of our model, using patient spe-
cific data, this paper attempts to gain some knowledge
by looking at population based data. The data are in
terms of risk ratios, the incidence of health factors and
typical pathogenesis of CHD. Some interesting insights
are revealed about possible interconnections of patho-
genesis underlying both CHD and periodontal disease.
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Methods
An integrated model was developed as part of a larger
research project [9]. This project was partially described
in previous articles dealing with certain subsets of the
research [8, 10, 11]. Briefly, an integrated model of CHD
and health factors was developed from existing litera-
ture. The model was then used to describe the actions of
some non-traditional health factors on CHD. This was
achieved by using a connection graph which visually
shows the relationship between CHD pathogenesis,
measurable biomarkers and the health factors.
Integrated model development
The integrated model of CHD was developed using a
systematic review of the literature for CHD pathogen-
esis, health factors, biomarkers and pharmacotherapeu-
tics. Unless a publication was cited more than 50 times,
the resulting dataset included results from 1998 until
2014 as these were deemed to contain the most relevant
data. The studies were also selected based on how well
they accounted for confounders such as age, sex, socio-
economic status and others.
During the systematic literature review PubMed, Sci-
ence Direct, Ebsco Host, and Google Scholar were
searched for publications with “coronary heart disease”
or “coronary artery disease” or “cardiovascular disease”
or “CHD” as a keyword and combinations with “lifestyle
effects”, “relative risk prediction”, “network analysis”,
“pathway analysis”, “interconnections”, “systems biol-
ogy”, “pathogenesis”, “biomarkers”, “conventional bio-
markers”, “drugs”, “therapeutics”, pharmacotherapeutics”,
“hypercoagulability”, “hypercholesterolaemia”, “hypergly-
caemia”, “hyperinsulinaemia”, “inflammation”, and “hyper-
tension” in the title of the study.
Also searched were all major relevant specialty jour-
nals in the areas of cardiology, alcohol consumption,
nutrition, cigarette smoking, physical exercise, oral
health, psychological stress, depression, sleep disorders,
endocrinology, psychoneuroendocrinology, systems biol-
ogy, physiology, periodontology, CHD, the metabolic
syndrome and diabetes.
This literature was consulted in detail and the research
on the pathogenetic pathways of CHD was extracted
therefrom. A total of 118 articles, books and studies
were identified as important to the explanation of the
pathogenesis of CHD. The information from these stud-
ies was thus combined in a graphical manner in order to
develop the integrated model of CHD.
The integrated model was populated by considering
health factors which were considered as either lifestyle
effects or comorbid health disorders. Only health factors
which have been associated with statistically significant
increases or decreases in CHD risk were included in the
model. The health factors considered were only those
which are measurable through biomarkers and could
conceivably be influenced by medication, prevention or
other treatment. Thus, other factors such as socio-
economic status were not considered. However, if future
models are created for risk prediction more factors such
as socio-economic status will have to be considered.
This resulted in nine health factors being considered
in the model, namely Alcohol, Food, Exercise, Smoking,
Oral health, Stress, Depression, Insomnia and Sleep
Apnoea [8, 9].
In brief, the systematic review of literature revealed
the pathological effects of various health factors on the
pathogenesis of CHD. This information was combined
to form a visual representation of the pathogenesis of
CHD as it is affected by these health factors. In this
study the integrated model was used to describe the pos-
sible integrated effects of periodontal disease on the
pathogenesis of CHD.
The integrated model of CHD schematically illustrates
the complexity of CHD and shows all theoretical patho-
genetic pathways between the health factors and CHD.
The model has been previously used to describe the ef-
fects of high carbohydrate diets on CHD [8], as well as
the possible mechanisms through which antidepressants
[11] and moderate alcohol consumption [10] may reduce
CHD risk.
Furthermore, as the model is already complex, con-
founders were treated as follows: they were compensated
for in the initial data but not included in the model.
Therefore, when selecting the data used for the model,
only the studies that best accounted for confounders
such as age, sex, socio-economic status and others were
used.
This encourages focus on a purely measurable bio-
marker driven model. Such a model, is not yet useful as
a practical model for population based risk. It does how-
ever give a good indication of the way in which the
interconnections between certain measurable factors
(biomarkers) and the CHD risk correlate. Potential refin-
ing of the model is described in the Discussion section.
Biomarker identification
In order to allow the model to quantify the functionally
measurable aspects of CHD pathogenesis, biomarkers
were included in the integrated model [8, 9]. The bio-
markers were only those whose measurement has been
associated with statistically significant increases or de-
creases in CHD risk. This resulted in 23 biomarkers
being considered in the model, namely triglycerides,
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), apolipoprotein-B (Apo B), leptin, C-reactive pro-
tein (hsCRP), interleukin-6 (IL-6), tumour necrosis
factor- α (TNF-α), growth-differentiation factor-15
(GDF-15), osteoprotegerin (OPG), myeloperoxidase
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(MPO), B-type natriuretic peptide (BNP), homocysteine, fi-
brinogen, troponins, urinary albumin-to-creatinine ratio
(ACR), glycosylated haemoglobin (HbA1c), insulin-like
growth factor-1 (IGF-1), adiponectin, cortisol, brain-
derived neurotrophic factor (BDNF) and insulin resistance.
Data selection
When selecting the data for the integrated model, only
articles using the following risk measures: relative risk
(RR), odds ratio (OR), or hazard ratio (HR) were consid-
ered. This study’s intention was to create an overarching
model rather than to conduct individual meta-analyses
of the individual biomarkers or lifestyle effects. Thus,
the risk data used in the model was taken from the most
recent and relevant meta-analyses of each biomarker. A
single high quality representative study was used where
no meta-analysis for CHD risk was available for a spe-
cific biomarker or lifestyle effect.
The risk data used in the model was also further se-
lected based on which meta-analysis adjusted for the
most confounding variables such as age, sex, socio-
economic status and others. This was done in order to
ensure that the effects of most of the potential con-
founders were adjusted for. However, since not all the
studies adjusted for the same confounders, this may,
have increased the heterogeneity between studies..
For the effects of changes in biomarkers the relative
risk (RR) was, where possible, extracted from the most
recent meta-analysis conducted on the specific bio-
marker. If no relevant meta-analysis was available, a suit-
able high quality study was selected instead. The RR
data included in the model was standardised to include
only RR data that was given per increase of 1-standard
deviation (SD) in the biomarker level. This was done in
order to limit errors in comparisons between biomarkers
and to prohibit the misrepresentation of risk due to the
selection of extreme exposure contrasts [7].
Pathway characterisation
In this study the integrated model was used to elucidate
the potential interactions between periodontal disease and
the pathogenesis of CHD. To achieve this, the pathogen-
esis of CHD in which periodontal disease could play a role
is described. A brief summation of the literature reviewed
to develop the integrated model is presented as the
“pathogenetic effects of periodontal disease” in the results
section.
To simplify the importance of these interactions a
connection graph was established for the relationship
between periodontal disease and CHD. The connection
graph is a graphic representation showing how the path-
ways underlying between CHD and periodontal disease
are related to the CHD biomarkers.
The connection graph displays the RR for a 1-SD
increase in all the biomarkers. Furthermore, the bio-
markers were divided into eight classes, namely vascular
function and neurohormonal activity, renal function, ne-
crosis, coagulation, oxidative stress, lipids, metabolic and
inflammation markers.
The pathogenesis of periodontal disease, as described
by the pathways in the integrated model, was used to de-
termine which of the biomarkers might be affected by
periodontal disease. This was indicated on the connec-
tion lines between “Oral health” and the biomarkers.
Activation of the pathways can be analysed through
measurement of the relevant biomarkers. Thus, to valid-
ate the connection graph, data from previous studies
investigating changes in serum biomarker levels in pa-
tients with periodontal disease was corroborated with
the biomarkers indicated in the connection graph.
Statistical analysis
Statistical analysis of the results was limited to the risk
ratios which were extracted from published studies for
the various biomarkers of CHD. All risk ratios were ex-
tracted to ensure that they were representative of a 1-SD
change in the serum biomarker. All risk ratios extracted
were converted to RR if given in odds or hazard ratios.
The study makes use of a non-traditional method of
graphically displaying the RR indicating a decrease in
risk. RR indicating an increasing risk is displayed as per
normal. Decreasing RR is transformed by using the in-
verse of the typically presented RR.
The non-traditional method was used due to the prob-
lems of explaining relative risk to an untrained person as a
result of the visual scaling of the traditional RR [8]. In this
article a conventional RR = 3 is presented as per normal,
as a 3-fold increase in risk while a conventional RR = 0.33
is presented as a 3-fold decrease in risk (1/0.33 = 3). This
method was used to convert between the RR data ex-
tracted from studies and the bar graphs presented in this
study.
Results
Integrated model of coronary heart disease
The integrated model of CHD which was developed in
the previous studies [8–11]. It is presented in Figure One
of the article by Mathews et al. [8]. In the integrated
model the pathways (pathogenesis of CHD) can be
tracked from where a specific health factor influences
the relevant tissue, to the end state of CHD. The path-
ways of the integrated model are thus a visual represen-
tation of previously published knowledge on CHD
pathogenesis.
The focus of this paper is on using the integrated
model to describe the interconnections of periodontal
disease on the pathogenesis of CHD. Thus, a more
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detailed discussion of Figure One of Mathews et al. [8],
relevant to periodontal disease, is given in following sec-
tions. This review therefore attempts to quantify the po-
tential CHD effect of periodontal disease by the
connection of these to an array of biomarkers which
represent increasing or decreasing CHD risk.
Biomarkers of coronary heart disease
Biomarkers can be used as indicators of an underlying
disorder and give an indication of the activation of
pathogenetic pathways [12–14]. Furthermore, the pre-
diction of the RR for CHD associated with a biomarker
[12–14] is enabled by the measurement of said bio-
marker’s levels. This can allow for an exploration of the
possible effects of periodontal disease on the pathogen-
esis of CHD by considering the measurement of typically
CHD biomarkers in patients with CHD.
The serological biomarkers which were used to
simplify the integrated model are given in Table three of
Mathews et al. [8]. Figure two of Mathews et al. [8] pre-
sents a comparison of the RR for CHD associated with
these biomarkers per 1-standard deviation (SD) increase
in the biomarker [8, 9].
Pathogenetic effects of periodontal disease
Figure One of Mathews et al. [8] indicates all possible
pathogenetic pathways between the considered lifestyle
effects and CHD. In the present paper we only appraise
the possible CHD effects of periodontal disease. These
are noted in Table 1 and will be described in detail.
Many of the potential pathogenetic effects of peri-
odontal disease on CHD have been postulated to be due
to the entry of bacteria or bacterial products into the
blood stream [5]. A common periodontitis associated
bacteria, Porphyromonas gingivalis (P.gingivalis), has
been found to invade endothelial cells [15] as well as
atheromatous tissues [16, 17]. This is one of the patho-
genetic links between periodontal disease and CHD as
shown by pathway: 5-23- P.gingivalis in the integrated
model in Figure One of Mathews et al. [8]. In order to
consider the overall effect of periodontal disease on
CHD we will therefore consider all pathogenetic links
between the two.
One of the possible links between P.gingivalis and
CHD, supported by in vitro testing, is through increased
platelet activity via a TLR2-dependent mechanism [18].
Pathway 5-23-P. gingivalis-43-periodontitis-64-platelet
Fig. 1 Potential interconnection of relative risk effects of periodontal disease and serological biomarkers for CHD. “ACR” denotes, albumin-to-creatinine
ratio; Trop, troponins; Fibrin, fibrinogen; MPO, myeloperoxidase; BNP, B-type natriuretic peptide; Cysteine, Homocysteine; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; Trigl, triglycerides; ApoB, Apolipoprotein-B; Adipon, adiponectin; HbA1c, glycosylated haemoglobin A1c; Cort,
cortisol; IGF-1, insulin-like growth factor-1; BDNF, brain-derived neurotrophic factor; GDF-15, growth-differentiation factor-15; CRP, C-reactive
protein; IL-6, interleukin-6; TNF-α, tumour necrosis factor-α; RANKL or OPG, osteoprotegerin
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factors-73-hypercoagulability in Figure One of Mathews
et al. [8] shows how increased platelet activity from peri-
odontal disease can lead to an increased possibility for
hypercoagulability, a hallmark of CHD.
Pathway 5-23-P. gingivalis-43-periodontitis-65-oxLDL-
51-hypercholesterolaemia in Figure One of Mathews et
al. [8] shows how periodontal disease can have an effect
on oxidised LDL cholesterol (oxLDL) due to the in-
creased reactive oxygen species (ROS) associated with
periodontal disease [19]. Increased ROS up regulates the
oxidation of LDL cholesterol to form oxidised LDL [2].
Increased ROS may also play a crucial role in the
link between periodontal disease and systemic inflam-
mation. Pathway 5-23-P. gingivalis-43-periodontitis-62-
ROS-85-inflammatory in Figure One of Mathews et
al. [8] shows how increased ROS can activate nuclear
factor-κB (NF-κB) and consequent production of
growth factors and pro-inflammatory cytokines [2]
leading to systemic inflammation.
It is also possible that chronic systemic inflammation
can further be up regulated by P.gingivalis, by causing
increased elevations in C-reactive protein [20], fibrino-
gen [21], tumour necrosis factor-α (TNF- α) and
intereukin-6 (IL-6) [4, 5] serum levels. These actions are
shown in Figure One of Mathews et al. [8] by 5-23-P.
gingivalis-periodontitis-41-TNFα/IL6-inflammatory state.
Increased and systemic inflammation could link peri-
odontal disease and a pro-atherogenetic state of insulin
resistance. Pathway 5-23-P. gingivalis-43-periodontitis-
41-TNFα/IL6-inflammatory state-60-insulin resistance in
Figure One of Mathews et al. [8] shows how the release
of pro-inflammatory cytokines such as TNF-α, IL-6 and




shows how periodontal disease could be linked to changes
in vasodilation. Increased insulin resistance as a result of
inflammation could affect vasodilation by impairing the
vasodilation effect of insulin [25, 26].
It is thus evident from the integrated model that there
are significant potential share underlying pathogenetic
links between periodontal disease and CHD. These are
largely in the form of increased inflammation and poten-
tial changes in hypercoagulability and insulin resistance.
The rest of this paper will attempt to quantify the im-
portance of the connections and links identified above
by considering the changes in biological markers.
Effects of periodontal disease
In the previous section we elucidated the pathogenetic
pathways underlying to CHD which are potentially acti-
vated by periodontal disease. Now we will link these
pathways to measurable CHD biomarkers. It is possible
that a pathogenetic pathway may be shared by both
CHD and periodontal disease. However periodontal dis-
ease may not have a measured effect on CHD risk bio-
markers for this pathway. This may indicate that the
pathogenetic pathway is not influenced by periodontal
disease in such a way which would increase CHD risk.
In an attempt to validate the theoretical pathways we
considered existing literature which has shown mea-
sured differences in the serological biomarkers of CHD
risk in patients with periodontal disease. Using this to
describe the potential connection between periodontal
disease and the serological biomarkers of CHD enables
the simplification of the integrated model into a ‘connec-
tion graph’. The connection graph in Fig. 1 shows all the
potential connections between periodontal disease and
the measurable serological biomarkers of CHD. The RR
values linked with the relevant biomarkers were given in
Table three of Mathews et al. [8].
The pathways from the integrated model (Figure One
of Mathews et al. [8]) which are regulated by periodontal
disease and described in Table 1 are thus shown on the
connecting lines in Fig. 1. Each pathway suggests the
manner in which the CHD biomarker is likely affected
by periodontal disease. Previously published research on
changes in serum biomarkers in patients with periodon-
tal disease was used in an attempt to validate the
Table 1 Putative effects of periodontal disease and salient CHD pathogenetic pathways
Pathways, and pathway numbers corresponding to those in Figure One of Mathews et al. [8] Refs.
a. 5-23-↑P. gingivalis-43-↑periodontitis-64-↑platelet factors-73-↑hypercoagulability a. [2, 4, 5, 64, 65]
b. 5-23-↑P. gingivalis-43-↑periodontitis-65-↑oxLDL-51-↑hypercholesterolaemia b. [2, 4, 5, 64, 65]
c. 5-23-↑P. gingivalis-43-↑periodontitis-62-↑ROS-85-↑inflammatory state c. [2, 4, 5, 64, 65]
d. 5-23-↑P. gingivalis-43-↑periodontitis-41-↑TNFα/IL6-↑inflammatory state d. [4, 5, 64, 65]
e. 5-23-↑P. gingivalis-43-↑periodontitis-41-↑TNFα/IL6-↑inflammatory state-60-↑insulin resistance e. [2, 64, 66, 67]
f. 5-23-↑P. gingivalis-43-↑periodontitis-41-↑TNFα/IL6-↑inflammatory state-60-↑insulin resistance-↑vasodilation f. [68]
↑ denotes up regulation/increase, ↓ denotes down regulation/decrease, x-y-z indicates pathway connecting x to y to z. FFA free fatty acids, IGF 1 insulin-like
growth factor-1, IL6 interleukin-6, LDL low-density lipoprotein, MAPK mitogen-activated protein (MAP) kinase, MCP 1 monocyte chemoattractant protein-1, NO nitric
oxide, oxLDL oxidised LDL, P. gingivalis Porphyromonas gingivalis, PI3K phosphatidylinositol 3-kinase, PI3K:MAPK ratio of PI3K to MAPK, ROS reactive oxygen
species, SMC smooth muscle cell, TNFα tumour necrosis factor-α, VCAM 1 vascular cell adhesion molecule-1
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connections between periodontal disease and the CHD
biomarkers.
The explanation of the pathogenetic pathways in
Table 1 would suggest that there should be a strong con-
nection between periodontal disease and the markers of
systemic inflammation. It is also evident from the con-
nection graph of periodontal disease (Fig. 1), that there
are a significant number of connections to the inflam-
matory biomarkers due to periodontal disease.
Numerous studies have noted increased serum levels
of CRP in patients with periodontal disease compared to
those without [20, 27–29]. One study [27] found eleva-
tions of CRP levels in the order of 30% when compared
to patients without periodontal disease. Increased CRP
levels are significantly associated with an increase in
CHD risk (See Table three of Mathews et al. [8]).
Additionally, there is production of proinflammatory
cytokines such as IL-6 and TNF-α in inflamed periodon-
tal tissue [30, 31], which can further antagonise a sys-
temic inflammatory response [32, 33]. Increased levels of
IL-6 and TNF-α are both linked to increased risks for
CHD (See Table three of Mathews et al. [8]).
In severe cases of inflammatory response, where in-
flammation has spread to the alveolar bone, proinflam-
matory cytokines can induce bone loss by increasing the
expression of RANKL [34] and thus influence the levels
of Osteoprotegerin (OPG) [35]. Decreased OPG levels,
as a surrogate of RANKL levels, have been found to be
significantly associated with increased CHD risk (see
Table three of Mathews et al. [8]) [36]. It is thus possible
that RANKL or OPG serum levels may serve as an indi-
cation of the severity of inflammation present due to
periodontitis.
The connection graph in Fig. 1 shows that a strong
connection between periodontal disease and inflamma-
tion is postulated and the abovementioned research con-
firms this. This indicates that it may be possible that a
systemic inflammatory response to periodontal disease
can antagonise CHD and CHD risk [12, 37].
Insulin resistance is postulated to be affected indirectly
by periodontal disease through the actions of inflamma-
tory cytokines [22–24]. Increased insulin resistance has
indeed been found to be associated with the severity of
periodontal infection [24]. Insulin resistance is however
known to increase CHD risk [38] and Fig. 1 shows the
connection between periodontal disease and insulin re-
sistance with reference to the pathway from the inte-
grated model of CHD (Figure One of Mathews et al. [8]).
It is known that chronic periodontal disease increases
reactive oxygen species (ROS) generation which in turn
depletes plasma antioxidants [2] and causes an oxidative
stress situation [39]. This has been noted by increases in
myeloperoxidase (MPO) in patients with chronic peri-
odontal disease [40, 41] and is shown by the connection
in Fig. 1. Oxidative stress induced by excess ROS could
increases CHD risk due to the increased oxidation of
LDL by ROS into oxidised LDL [42].
Oxidised LDL has been implicated in the pathogenesis
of atherosclerotic plaques by facilitating cholesterol uptake
by macrophages and the formation of foam cells in the
endothelium [42, 43]. Therefore, MPO as an indicator of
oxidative stress is attributed with a significant increased
risk for CHD (See Table three of Mathews et al. [8]) [44].
Increases in serum fibrinogen levels have been found
in patients with chronic periodontitis [45]. It is known
that elevated serum levels of fibrinogen are implicated in
poor CHD prognosis and increased CHD risk [46]. In-
creased fibrinogen caused by periodontal infection may
cause an underlying increase in CHD risk by increasing
the possibility for hypercoagulability as shown in Fig. 1.
Discussion
The use of an integrated systematic approach to better
understand CHD elucidates the potential pathways
which could lead to the hallmarks of CHD and a CHD
event. It is evident that the pathological effects of peri-
odontal disease are in some cases similar to or antagon-
ise the pathogenesis of CHD.
It is apparent from Fig. 1 that there are several pos-
sible links between periodontal disease and CHD. Con-
nections are evident between periodontal disease and
CHD biomarkers through the hallmarks of hypercoagu-
lability, and an inflammatory state.
From the connection graph (Fig. 1) it would appear
that these connections may be relevant to CHD risk.
However, what is not apparent is whether these connec-
tions are relevant to increased risk for CHD and if the
relationship is causal. It is possible that these links may
be mediated by direct pathological effects of periodontal
bacteria or through the effects of underlying disorders
such as inflammation.
These relationships should therefore be tested on a
population basis in suitable trials. For instance, a study
which determines the relationship between periodontal
disease, CHD and serum biomarker levels would be
needed to more clearly determine this relationship. Such
a study would need to recruit a sample population hav-
ing periodontal disease and note changes in the relevant
biomarker levels with varying levels of periodontal dis-
ease. Furthermore, the study population must be large
enough to limit confounding and the study period long
enough for CHD incidents to occur. Unfortunately such
studies are outside the scope of our research group.
Smaller studies could identify the effect of the success-
ful treatment of periodontal disease on inflammatory
markers, insulin sensitivity and markers of coagulation
and oxidative stress (Fig. 1). While these will not sub-
stantiate a causal relationship between CHD and oral
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health they will show the relationship between the
underlying pathogenetic pathways and periodontal dis-
ease with reference to known measurable CHD risk
biomarkers.
Furthermore, the model presented may elucidate im-
portant CHD biomarkers which should be measured in
patients with periodontal disease to more adequately
screen for CHD risk, namely HOMA, TNF-α, CRP, IL-6,
GDF-15, OPG, MPO and fibrinogen. This could lead to
better treatment of patients at risk of CHD. In addition
other risk confounders such as age, sex and socioeco-
nomic status would need to be considered.
These other risk considerations are important for fur-
ther development of the integrated model of CHD. For in-
stance, it is known that some of the health factors we have
included in the model are affected by confounders such as
age, sex and socioeconomic status [47–49]. In particular,
socioeconomic status is a substantial confounder to using
the model on a population basis for risk prediction. It has
the potential to present a significant confounding effect
on all the health factors [49–53].
These further risk considerations should be included if
the model is used for risk prediction on a population
scale. It is important because these further consider-
ations such as socioeconomic status are mediators of the
health factors in the model and thus may present a top
down approach to intervention.
Currently the integrated model is based purely on
available measurable biomarker data and as such it is
not meant as a practical model. Thus, the current model
cannot be used for practical risk prediction of large pop-
ulations until factors such as age, sex, socio-economic
status and others are taken into account [54]. However,
it is theorised that the model could be validated on a pa-
tient specific basis by comparing the patient specific bio-
markers and health factors with themselves over time.
Such an approach would circumvent the problem of
confounders such as such as age, sex, socio-economic
status by using the patient as their own ‘control’.
A study could be conducted which attempts to valid-
ate the theoretical pathways by comparing a patient with
themselves at different times where by different health
factors or severity of health factors may be applicable.
Such a study will require a smaller sample size but the
results of the study would not likely be applicable to a
greater population. However, it could validate the theor-
etical model to such a degree that large trials may prove
worthwhile.
As such the current model is based entirely on a
‘theoretical person’ devoid of external factors. This the-
oretical model is built on data taken from external
sources with an emphasis on having removed the most
confounders in order to focus just on the underlying
connections. The current integrated model is therefore
more geared towards showing that these interconnec-
tions exist between health factors and CHD in a holistic
sense. These should be studied further in preparation for
the creation of a practical tool.
The intention of the model was to determine the likely
method of action for a possible causal relationship be-
tween periodontal disease and CHD. In this regard the
model itself shows why a causal relationship has not yet
been demonstrated due to the interconnected nature of
the disorders. The model shows how many variables me-
diate or confound the relationship. Each of these vari-
ables will have to be accounted for in studies of suitable
size and design.
However, even with these shortcomings, numerous
studies have alluded to the fact that periodontal disease
is associated with a statistically significant increase in
CHD risk [2–6]. The effect of periodontal disease on
CHD biomarkers as shown in Fig. 1 indicates some of
the effects which could serve to explain some of the risk
for CHD. It is known that when increases in these bio-
markers are considered in isolation they are associated
with increased risk for CHD [36, 38, 46, 55, 56].
The importance of these relationships are however not
immediately clear. An example may provide some con-
text to their importance. An interesting comparison to
make is between the relative risk for CHD associated
with elevated LDL-cholesterol and the relative risk for
CHD associated with periodontal disease. This in com-
bination with the percentage of the population at risk of
high cholesterol or periodontal disease should make the
comparison interesting.
Previous studies have shown that the increased CHD
risk attributed to periodontal disease is a relative risk of
1.34 (confidence interval 1.27 to 1.42) [6]. Other studies
have shown that the risk for typical elevations (1-SD
above the mean) in LDL-cholesterol is 1.25 (confidence
interval 1.18 to 1.33) [57]. The study mean for LDL-
cholesterol was 115.5 mg/dl and 1-SD was 35.0 mg/dl so
this relative risk correlates to a LDL-cholesterol level of
150.5 mg/dl.
Considering that moderate periodontitis is present in
30.0% of the adult population of the United States [58]
there is a significant 34% greater risk for them than
those without periodontal disease. Knowing that LDL-
cholesterol is widely regarded as the first indication of
CHD risk [57, 59, 60] it would stand to reason that
many more people are at risk due to high levels of LDL-
cholesterol. If we look at the research 31.7% of the
United States population is at risk of high LDL-
cholesterol (above 130 mg/dl) [61]. This equates to an
increased risk of less than 25% (1.25 for LDL greater
than 150 mg/dl).
The CHD risk associated with LDL-cholesterol serum
levels have resulted in substantial initiatives aimed at
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reducing LDL-cholesterol to reduce CHD risk [59, 62].
Considering that the potential CHD risk for periodontal
disease may be even greater would it not be appropriate
to engage in similar research undertakings to investigate
if periodontal disease should be positioned as an import-
ant risk factor for CHD?
Various studies have investigated the effect of periodon-
tal treatment on an array of CHD biomarkers. It was
found that periodontal treatment significantly improved
biomarkers of CHD [63]. However, causality between peri-
odontal disease and CHD has not been suitably tested. If a
causal relationship between periodontal disease and CHD
could be substantiated it would elevate periodontal disease
to an important CHD risk factor.
Conclusion
Although there is evidence that periodontal disease is
associated with a higher risk of CHD, all the possible ef-
fects on CHD pathogenesis are not available in a detailed
integrated model. Such a model should help provide fur-
ther insight. A high level conceptual model was thus de-
veloped which shows possible links of periodontal
disease with the pathogenesis, hallmarks and biomarkers
of CHD.
It was shown that periodontal disease has significant
physiological effects which are similar to or antagonise
the pathogenesis of CHD. Important effects are in-
creased inflammation, increased coagulation and insulin
resistance. These pathological actions are backed up by
the changes which have been noted through measured
biomarkers.
These pathways and actions may explain why a signifi-
cant risk for CHD has been observed in patients with
periodontal disease. This is specifically important con-
sidering the large percentage of the United States popu-
lation which have some form of periodontal disease.
However, more research is needed to conclusively sub-
stantiate a causal link between periodontal disease and
CHD.
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